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Abstract
Introduction: Chronic obstructive pulmonary diseases (COPD) have some sys-
temic effects including systemic inflammation, nutritional abnormalities, skele-
tal muscle dysfunction, and cardiovascular, skeletal and neurological disorders.
Some studies have reported the presence of peripheral neuropathy (PNP) at an
incidence of 28-94% in patients with COPD. Our study aimed to identify whether
PNP affects exercise performance and quality of life in COPD patients.
Material and methods: Thirty mild-very severe patients with COPD (male/female
= 29/1, mean age = 64 ±10 years) and 14 normal subjects (male/female = 11/5,
mean age = 61 ±8 years) were included in the present study. All subjects under-
went pulmonary function testing (PFT), cardiopulmonary exercise testing, elec-
troneuromyography and short form 36 (SF-36).
Results: Peak oxygen uptake (PeakVO2) was lower in COPD patients (1.15 ±0.53 l/min)
than healthy subjects (2.02 ±0.46 l/min) (p = 0.0001). There was no PNP in
healthy subjects while 16 (53%) of the COPD patients had PNP . Forced expira-
tory volume in 1 s (FEV1) and PeakVO2 were significantly different between
patients with PNP and those without (p = 0.009, p = 0.03 respectively). Quali-
ty of life of patients with PNP was lower than that of patients without PNP 
(p < 0.05). 
Conclusions: The present study demonstrates the exercise limitation in COPD
patients with PNP . Thus, presence of PNP has a poor effect on exercise capaci-
ty and quality of life in patients with COPD. Furthermore, treatment modalities
for PNP can be recommended to these patients in order to improve exercise
capacity and quality of life.
Key words: chronic obstructive pulmonary diseases, peripheral neuropathy, exer-
cise capacity, quality of life.
Introduction
Chronic obstructive pulmonary diseases (COPD) are mainly character-
ized by the presence of airflow limitation because of airway inflammation
and remodeling. Parenchymal destruction and the development of emphy-
sema are often associated with COPD in many patients [1]. Furthermore,
COPD has many important systemic effects during the natural course of
disease secondary to multiple factors such as systemic inflammation,
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oxidative stress, and hypoxemia [2]. Some of these
effects are nutritional abnormalities, skeletal mus-
cle dysfunction, anemia and other abnormalities
including cardiovascular, skeletal and neurological
disorders [3]. 
Exercise limitation is a common problem in
COPD patients which negatively influences health-
related quality of life [4]. To date, ventilatory insuf-
ficiency, increased ventilatory requirement, and
skeletal muscle dysfunction secondary to multiple
factors have been reported as the main causes of
exercise limitation in COPD patients [5]. 
Several studies have reported that peripheral
neuropathy (PNP) could occur at an incidence of
28-94% in patients with COPD [6-9]. Smoking, long
lasting hypoxia, and age have been found to be
contributing factors for the development of PNP in
COPD patients [6-8]. However, the clinical impor-
tance of PNP is still unclear in these patients. So
far, effects of PNP on exercise limitation in COPD
patients have not been investigated in the litera-
ture according to our knowledge. Based on the
above, we hypothesized that peripheral neuropa-
thy can play a role as one of the factors limiting
exercise capacity in COPD patients. 
For this purpose, we investigated the relation-
ships among peripheral neuropathy, exercise capac-
ity, and quality of life in patients with mild to very
severe COPD and normal subjects.
Material and methods
Study population 
Thirty stable patients with mild to very severe
COPD (male/female = 29/1, mean age = 64 ±10
years) and 14 healthy volunteer subjects (male/
female = 11/3, mean age = 61 ±8 years) were
enrolled in this cross-sectional study. Diagnosis of
COPD was based on current Global Initiative for
Chronic Obstructive Lung Disease (GOLD) guide-
lines [1]. At the baseline, 6 (20%) of the patients
were in mild stage, 11 (36.7%) were in moderate
stage, 11 (36.7%) were in severe stage, while 
2 (6.7%) were in very severe stage of the disease.
Patients with post-bronchodilator forced expirato-
ry volume in 1 s (FEV1) < 80% of the predicted val-
ue and FEV1/forced vital capacity (FVC) < 70% were
included in the study [10]. All COPD patients were
ex-smokers and all healthy subjects were non-
smokers in this study. Patients with a history of dia-
betes mellitus, alcoholism, chronic renal failure,
malignancy, any hereditary disorders affecting
peripheral nerves, intake of any neurotoxic drug, or
history of any traumatic lesion affecting peripher-
al nerve functions, and patients who were unable
to pedal a cycle ergometer, as well as active smok-
ers, were all excluded from the study. 
In our study population, all mild to very severe
COPD patients were receiving inhaled long-acting
β2-agonists and/or anticholinergic agents and/or
theophylline (oral route). Fourteen of the patients
were receiving additional inhaled corticosteroids.
All subjects performed pulmonary function test-
ing including dynamic and static lung volumes, car-
diopulmonary exercise testing (CPET), electrophys-
iological studies (electroneuromyographic – ENMG),
and the Short Form-36 (SF-36) questionnaire. All
subjects were informed and signed the patient’s
consent form. Sixteen COPD patients with PNP in
the stable period (group 1), 14 COPD patients with-
out PNP in the stable period (group 2) and 14
healthy subjects without smoking history as a con-
trol group (group 3) were included in the study.
The Short Form-36 questionnaire
The Short Form-36 (SF-36) questionnaire is
a measure of general quality of life (QOL) that has
been validated in patients with dilated cardiomy-
opathy. This questionnaire has 36 questions to
assess the patient’s ability to perform vigorous
activities and activities of daily living and to par-
ticipate in social, family, and occupational activities.
Eight scales are used to describe domains of phys-
ical function, social function, physical and emotional
role function, mental health, bodily pain, vitality,
and general health perception. The physical and
mental components of these scales can be com-
bined into physical and mental composite scores.
The scores are recorded on a scale ranging from
zero to 100; higher scores correspond to a more
favorable QOL. Responses to the SF-36 were scored
by means of a computer algorithm [11]. 
Pulmonary function testing
Spirometry was performed prior to exercise test-
ing. A clinical spirometer (SensorMedics Vmax spec-
tra 229, Bilthoven, The Netherlands) was used for
all assessments, and a laboratory technician
demonstrated each respiratory maneuver for the
subject before testing. Each subject performed
a maximal expiratory flow maneuver in the sitting
position. The FEV1 and FVC were measured, and the
FEV1/FVC ratio was then calculated. Patients were
coached by an experienced technician to perform
forced expirations until 3 acceptable measurements
were obtained and the best result was recorded.
Each recorded result was expressed as a percent-
age of the predicted value for that parameter. Total
lung capacity (TLC) was measured by the multiple
nitrogen washout method [12, 13]. The GOLD crite-
ria were used to classify severity of COPD [12]. 
Cardiopulmonary exercise testing
The CPET was performed using a cycle ergome-
ter (ergo-metrics 900, SensorMedicsTM, Bilthoven,
The Netherlands). Subjects were told not to eat or
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drink for 2 h before the test. The gas analyzer was
calibrated before each test with 2 standardized gas
mixtures (26% O2 + balanced N2 and 4% CO2 + 16%
O2 + N2). A facemask connected to a low-resistance
unidirectional valve (Rudolph Face Mask for Exercise
TestingTM; Hans Rudolph Inc., Kansas City, MO, USA)
was placed on the subject’s face without leakage.
The incremental exercise testing protocol consisted
of a 3-min baseline period, followed by a 3-min
warm-up period (up to 60 rpm pedaling), and then
the work rate was increased by 10 W for each minute
periodically. The data were recorded using an auto-
mated exercise testing system (Desktop Diagnos-
tics/CPX; Medical Graphics Corporation, St. Paul, MN,
USA). The maximum performed work rate that a sub-
ject sustained for 20 to 30 s was recorded. Each sub-
ject’s electrocardiogram, arterial pressure, and oxy-
gen saturation were monitored continuously during
the test. Peak oxygen uptake (peak VO2), peak CO2
output, and VE/VCO2 were all recorded. All values
were obtained from continuous 10-s averages [14]. 
Electrophysiological study
Electrodiagnostic examination was performed
using the Synergy (Medelec, Surrey, UK) EMG sys-
tem. Limb temperature was maintained above 32°C
using a warm compress if needed during the nerve
conduction studies. Electrodiagnostic tests includ-
ed conventional motor and sensory nerve conduc-
tion studies in right upper and bilateral lower limbs,
determination of minimal F-wave latency, H-reflex
testing from the soleus muscle and blink reflex test-
ing from orbicularis oculi muscles. 
Motor nerve conduction studies included right
median and ulnar, bilateral peroneal and tibial
nerves, using percutaneous stimulation and record-
ing. Sensory nerve conduction studies included right
superficial radial and bilateral superficial peroneal
and sural nerves using percutaneous stimulation
and recording. Sensory nerve action potentials
(SNAPs) were recorded using antidromic technique.
The H reflex was recorded from the soleus/gas-
trocnemius muscles by stimulating the tibial nerve
at the popliteal fossa. Blink reflexes were recorded
from the orbicularis oculi of both sides while elec-
trical stimulation of the supraorbital nerves was
applied. Measured variables were amplitudes (μV)
of antidromic sensory nerve action potentials
(SNAPs), distal motor latencies (DMLs) (ms), ampli-
tudes (mV) of compound muscle action potentials
(CMAPs), F-wave minimum latencies (ms), H-reflex
latency (ms), amplitude and ratio of H response,
and motor response (M) amplitude (mV). 
Statistical analysis
The SPSS program (SPSS version 12.0; SPSS Inc.,
Chicago, IL, USA) was used for the statistical analy-
ses. Continuous data are presented as means ±
standard deviation. The unpaired Student t test was
used to analyze the effects of continuous variables.
Pearson χ2 test was employed for the analysis of
categorical variables and results are expressed as
n and %. More than two groups in which variables
were normally distributed with homogeneous group
variances were compared by using one-way analy-
sis of variance (ANOVA) and Tukey test was used
for post-hoc analysis. A p value below 0.05 was con-
sidered significant. 
The study was approved by the institutional eth-
ical committee. The research protocol also complies
with the Helsinki Declaration of 2000.
Results
Demographic and clinical characteristics of the
patients and the healthy subjects are presented in
Table I. All of the patients with COPD had smoking
history, with a mean value of 45.9 ±19.2 pack years.
With regard to SF-36 life quality assessment, phys-
ical activity, difficulty in role playing, general health
and vitality parameters were found to be lower in
patients with COPD than in control subjects (Table I).
Of the SF-36 life quality questionnaire parameters,
physical functioning (PF), role-physical (RP), vitali-
ty (VT) and social functioning (SF) were found to
be significantly lower in COPD patients than in con-
trol subjects (p < 0.05) (Table I). Electrophysiolog-
ical studies (ENMG) were performed in all of the
study population and PNP was identified in 16
(53%) of 30 patients with COPD. Eight of the
patients had mild axonal sensorimotor neuropa-
Parameter COPD  Healthy  Value of p
group subjects 
(n = 30) (n = 14)
Sex 
Female 1 5 
Male 29 9 
Age [years] 64 ±10 61 ±8 0.38
BMI [kg/m2] 25.2 ±4.3 28.7 ±3.5 0.014
Peak VO2 [l/min] 1.1 ±0.5 2.02 ±0.5 0.0001
FEV1 [l] 1.6 ±0.7 3.9 ±0.8 0.0001
FEV1 (% predicted) 56.1 ±21.8 123.9 ±15.9 0.0001
FVC (% predicted) 97.0 ±23.0 130.8 ±16.7 0.0001
FEV1/FVC 45.3 ±13.6 79.6 ±6.8 0.0001
FEF25-75 18.6 ±13.9 102.9 ±28.3 0.0001
(% predicted)
TLC (% predicted) 98.8 ±23.5 126.6 ±13.2 0.001
PNP 16  (53%) 0 0.0001
Table I. Demographic, clinical characteristics and 
SF-36 life quality questionnaire parameters of the
patients and control subjects
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thy, 1 had moderate to severe axonal-sensorimo-
tor neuropathy, one had mixed type, and 6 had
mild axonal-sensorial neuropathy. None of these
patients had clinical symptoms of neuropathy
including numbness, prickling or tingling in the toes
or fingers, burning, freezing, throbbing and/or
shooting pain. In none of the healthy controls was
PNP detected.
When compared to controls the frequency of
PNP was significantly higher in COPD patients 
(p < 0.001) (Table I). In COPD patients peak VO2 and
FEV1 values were significantly lower in those who
had PNP than those without (0.99 ±0.5, 1.4 ±0.3
respectively; p = 0.03) (Figures 1 and 2). In patients
with COPD no significant relation was detected
between PNP development and age, body mass
index, smoking and PFT parameters (p > 0.05).
Using the SF-36 questionnaire for life quality
assessment, PF and MH values were found to be
significantly lower in COPD patients who had PNP
than in those without (p < 0.05) (Table II). 
Comparisons of the parameters among three
groups are outlined in Table III. All pulmonary func-
tion test results and peak VO2 values were signifi-
cantly different among the three groups (Figures 
1 and 2). SF-36 questionnaire parameters were low-
est in COPD patients with PNP . Patients with COPD
and PNP were demonstrated to have significantly
lower values of peak VO2, FEV1, PF, RP and MH than
those of COPD patients without PNP and control
subjects (Table III). 
Discussion
The COPD has some poor systemic effects
which affect quality of life and exercise capacity in
COPD patients secondary to its clinical effects from
systemic inflammation [3, 5-17]. Although the ori-
gin of systemic inflammation is still unclear, some
potential mechanisms have been proposed, includ-
ing the effect of tobacco [15, 16], an increased
inflammatory process spreading to the systemic
circulation [5-17], lung hyperinflation, skeletal mus-
cle dysfunction [18], tissue hypoxia [19] and the
bone marrow [2, 20]. To the best of our knowledge,
there is no study researching the clinical effect of
PNP in COPD patients. In the present study, we
investigated the effects of PNP on exercise capac-
ity and quality of life in mild to very severe COPD
patients. 
In our study population, we had a much higher
number of males than females in the COPD group.
In a recent study the COPD rate was reported as
four times higher in males than females in our
country (80 of 1160 subjects had a diagnosis of
COPD). Total smoking, biomass, and occupational
exposure were also found to be overwhelmingly
higher in males than in females in the same study
(16.1% and 3.9% respectively). Smoking was also at
a higher rate in males than females (57.2% and
25.5% respectively) [21]. Therefore, we suggest that
this result could be attributed to higher incidence
of COPD in males in our country. 
In the present study peripheral neuropathy has
occurred at an incidence of 53% in patients with
COPD while an incidence of 28-94% was reported
SF-36 parameters COPD  Healthy Value of p
group subjects
(n = 30)  (n = 14)
Physical functioning 62.2 ±29.7 87.1 ±17.7 0.007
Difficulty in role  53.7 ±42.5 91.3 ±26.9 0.005
playing
Pain 76.7 ±26.2 81.0 ±19.9 0.59
General health 52.0 ±23.0 69.7 ±15.6 0.01
Vitality 64.6 ±19.4 77.8 ±15.0 0.03
Social functioning 80.5 ±24.5 85.9 ±9.6 0.44
Emotional well-being 54.3 ±37.1 69.0 ±27.6 0.2
Mental health 69.3 ±21.8 71.1 ±13.3 0.7
Table II. Comparison of the COPD patients with and
without PNP with regard to demographic and clini-
cal characteristics and SF-36 questionnaire param-
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in the literature [6, 7, 9]. Consistent with the previ-
ous studies, neuropathic involvement was axonal
and predominantly sensory with milder involve-
ment of motor nerves in our study. Faden et al.
reported electrophysiological evidence of peripher-
al nerve dysfunction in 20 (87%) of 23 patients with
COPD who were active smokers throughout the
study [6]. Kayacan et al. reported PNP at an inci-
dence of 93.8% in 19 severe to very severe and 13
mild to moderate COPD patients. Nineteen of the
severe to very severe COPD patients were also
hypoxemic in their study population [7]. Agrawal et
al. studied 30 smoker COPD patients and found that
17% of patients had PNP which was related to
habits of smoking and the duration of illness,
although no data about COPD stages of patients
were provided in their study [9]. In our study all of
the patients had mild to very severe COPD and all
were ex-smokers. In addition, severity of airway
obstruction was related to the presence of PNP,
suggesting that PNP was related to severity of dis-
ease. Considering all these data, we suggest that
different reported PNP frequencies of these stud-
ies could be due to the variety of COPD stages,
hypoxemia and smoking status of the study popu-
lations. 
Some studies have reported that smoking could
be a factor for development of PNP in COPD
patients [6, 9]. Nevertheless, we found no differ-
ence between patients with PNP and without in
terms of smoking exposure in comparison to the
literature. Additionally, presence of PNP was relat-
ed to the severity of disease, which was measured
by FEV1 in our study. Other possible causes of PNP
were also excluded due to the exclusion criteria of
our study. Hence, we suggest that an inflammato-
ry process spilling over into the systemic circula-
tion [5, 17] might be a contributing factor for devel-
opment of PNP . 
Although mechanisms of exercise limitation have
been researched in several studies [22-31], the clin-
ical importance of peripheral neuropathy in the
pathogenesis of decreased exercise capacity has
not been investigated previously in COPD patients.
Peripheral neuropathy generally consists of the tri-
ad of sensory changes, hyporeflexia and distal
and/or proximal muscle weakness resulting in
decreased exercise capacity of patients. Certain
types of neuropathy may show widespread senso-
ry symptoms, others may begin with more promi-
nent proximal weakness, and mild cases may be
subclinical. In the present study, peak VO2 was
found to be significantly lower in COPD patients
than in healthy subjects. Moreover, peak VO2 was
more significantly decreased in COPD patients with
PNP than in patients without PNP . Peak VO2 was
also related to the presence of PNP and severity of
disease in our COPD patients. Based on these
results, we suggest that PNP may be a systemic
effect of COPD which could be a contributing fac-
tor to the decreased exercise capacity of these
patients. 
Some studies have reported that health related
quality life of COPD patients decreased due to [11,
32, 33] numerous factors including dyspnea, sever-
ity of airway obstruction, hypoxemia, fatigue, mus-
cle wasting, exercise limitation and environmental
factors [33-36]. In our study the population life qual-
ity score was lower in patients with COPD who did
not have any clinical symptoms of polyneuropathy
than in healthy subjects. Furthermore, the decrease
in quality of life scores was significant, especially
in patients with PNP versus without. For this rea-
son, we believe that even if the patients with COPD
do not have any complaint suggesting neuropath-
ic involvement, an electrophysiological study should
be conducted to rule out PNP .
Certain markers of systemic inflammation, such
as C-reactive protein (CRP), tumour necrosis factor α
(TNF-α) and interleukin 6 (IL-6), have been shown
Parameters Group 1G roup 2G roup 3
COPD C OPD Controls
with PNP without PNP (n = 14)
(n = 16) (n = 14)
Age [years] 66.4 ±9.3 60.5 ±9.4  61 ±8
BMI [kg/m2] 24.0 ±4.5a 26.1 ±3.7 28.7 ±3.5
Smoking pack  49.6 ±20.4a 42.3 ±18.9b 0
[years]
Peak VO2 [l/min] 0.99 ±0.5a 1.4 ±0.3b 2.0 ±0.4
FEV1 [l] 1.63 ±0.9a 1.7 ±0.5b 3.8 ±0.8
FEV1 (% predicted) 54.0 ±27.4a,c 60.7 ±14.7b 123.9 ±15.9
FVC (% predicted) 97.4 ±24.2a 99.0 ±17.2b 130.8 ±16.7
FEV1/FVC 42.2 ±15.3a 48.8 ±10.7b 79.5 ±6.8
FEF25-75 19.0 ±17.9a 19.0 ±10.4b 102.9 ±28.3
(% predicted)
Physical 51.1  ±28.7a,c 74.0 ±21.1 87.1 ±17.7
functioning
Difficulty in role  51.9 ±38.8a 65.1 ±44.8 91.2 ±26.9
playing
Pain 79.0 ±26.8 83.6 ±20.8 81.0 ±19.9
General health 51.3 ±26.3 56.8 ±16.1 69.7 ±15.6
Vitality 61.9 ±21.0 73.1 ±13.6 77.8 ±15.2
Social functioning 72.6 ±19.6 89.7 ±13.4 85.9 ±9.6
Emotional  51.2 ±22.2 60.6 ±29.1 69.0 ±27.6
well-being
Mental health 63.7 ±23.7c 79.6 ±14.2 71.1 ±13.3
Table III. Comparison of demographic and clinical
characteristics and SF-36 questionnaire parameters
among three groups
ap < 0.05 vs. group 3, bp < 0.05 vs. group 3, cp < 0.05 vs. group 2
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to be elevated in stable patients with COPD in sev-
eral studies [5, 15, 17, 37-39]. In addition, systemic
inflammation was found to be related to systemic
effects of COPD patients. Therefore, it could be
hypothesized that PNP could be a result of systemic
inflammation in these patients. There is a single
study researching the relation between inflamma-
tory cytokines and PNP, which found no relation
between peripheral nervous system involvement
and proinflammatory cytokines such as TNF-α, 
IL-6, insulin-like growth factor 1 (IGF-1) and CRP in
COPD patients [40]. Although forty COPD patients
were included in that study, PNP was detected in
only 16 of the COPD patients. Hence, the authors
declared that they could not compare patients with
and without neuropathy due to the limited number
of patients with neuropathy. Therefore, we suggest
that their study may not reflect the relation
between systemic inflammation and neurophysio-
logical effects of COPD. Further studies are needed
to research the relation between severity of inflam-
mation and peripheral nervous system involvement
in a larger number of COPD patients with PNP to
support our hypothesis.
In conclusion, COPD is associated with numer-
ous and significant systemic effects that impact
a wide range of extrapulmonary tissues and organ
systems. PNP as one of the complications of COPD
related to poor life quality and exercise limitation
should be investigated and treatment modalities
for PNP can be recommended to these patients to
improve exercise capacity and quality of life.
The number of patients enrolled is low. The dis-
tribution of the patients with regard to severity of
COPD is not uniform. Such factors make it difficult
to reach a firm conclusion. We also could not eval-
uate the role of systemic inflammation markers on
PNP and quality of life in these patients. An addi-
tional control group of subjects with PNP was not
included in the study. Thus we could not determine
the effects of PNP on FEV1 and exercise capacity in
healthy control subjects. Further studies and obser-
vations with larger numbers of subjects are need-
ed to explore these associations.
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